• Matinas BioPharma signed a definitive deal to sell its Nanotechnologies unit, including MAT2203 and the LNC drug-delivery platform, to Azurity Pharmaceuticals.
• Consideration includes USD 4 million upfront cash, up to USD 17.5 million in milestones, and mid-single-digit royalties on MAT2203 net sales and certain licensing proceeds.
• Former Series A preferred holders are entitled to 7.5% of amounts received from Azurity under previously issued royalty rights certificates.
• Closing requires stockholder approval and is tied to completion of the planned business combination with GH Power.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.